GSK secures exclusive China partnership for bepirovirsen, targeting 75M chronic hepatitis B patients

summarizeSummary

GSK has partnered with China's SBP Group (CTTQ) for the exclusive commercialization of bepirovirsen, a potential first-in-class chronic hepatitis B treatment, in mainland China. This collaboration provides immediate access to over 5,000 medical centers, significantly accelerating market penetration for a drug under priority review.

check_boxKey Events

• Exclusive China Collaboration

  GSK has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), for the commercialization of bepirovirsen in mainland China.

• Enhanced Market Access

  CTTQ, a market leader in hepatology in China with a broad commercial footprint, will be responsible for importation, distribution, hospital access, and promotional activities, providing scaled access to over 5,000 medical centers.

• Key Drug for Large Market

  Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B (CHB), a disease affecting an estimated 75 million people in China and a national health priority.

• Advanced Regulatory Status

  Bepirovirsen has already received Breakthrough Therapy designation in China and was accepted for Priority Review in April 2026, supported by positive Phase III trial results.

auto_awesomeAnalysis

This collaboration is a critical step for GSK to maximize the commercial potential of bepirovirsen, a highly anticipated drug for chronic hepatitis B, in the vast Chinese market. By leveraging CTTQ's extensive local network and expertise, GSK significantly de-risks the launch and ensures rapid, scaled access to patients. This strategic move positions bepirovirsen for strong sales upon approval, addressing a major public health priority in China and bolstering GSK's specialty medicines portfolio.